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Abbreviations 
CINV -  Chemotherapy-Induced Nausea and Vomiting 
GIT – Gastrointestinal Tract 
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5-HT3 -  5-Hydroxytryptamine 
NK-1 -  Neurokinin 1 
NF-κB - nuclear factor kappa-B 
Abstract 
Despite advances in anti-emetic therapy, chemotherapy-induced nausea and vomiting (CINV) 
still poses a significant burden to patients undergoing chemotherapy. Nausea, in particular,  is 
still highly prevalent in this population. Ginger has been traditionally used as a folk remedy for 
gastrointestinal complaints and has been suggested as a viable adjuvant treatment for nausea and 
vomiting in the cancer context. Substantial research has revealed ginger to possess properties that 
could exert multiple beneficial effects on chemotherapy patients who experience nausea and 
vomiting. Bioactive compounds within the rhizome of ginger, particularly the gingerol and 
shogaol class of compounds, interact with several pathways that are directly implicated in CINV 
in addition to pathways that could play secondary roles by exacerbating symptoms. These 
properties include 5-HT3, substance P and acetylcholine receptor antagonism; anti-inflammatory 
properties; and modulation of cellular redox signalling, vasopressin release, gastrointestinal 
motility, and gastric emptying rate. This review outlines these proposed mechanisms by 
discussing the results of clinical, in vitro and animal studies both within the chemotherapy 
context and in other relevant fields. The evidence presented in this review indicates that ginger 
possesses multiple properties that could be beneficial in reducing chemotherapy-induced nausea 
and vomiting. 
D
ow
nl
oa
de
d 
by
 [N
ati
on
al 
Li
br
ary
 of
 M
ed
ici
ne
] a
t 0
6:3
9 1
3 J
un
e 2
01
6 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 3 
Keywords: ginger, nausea, chemotherapy, CINV, vomiting 
  
D
ow
nl
oa
de
d 
by
 [N
ati
on
al 
Li
br
ary
 of
 M
ed
ici
ne
] a
t 0
6:3
9 1
3 J
un
e 2
01
6 
ACCEPTED MANUSCRIPT 
ACCEPTED MANUSCRIPT 4 
Introduction 
Chemotherapy-induced nausea and vomiting (CINV) is a significant burden for patients 
undergoing anticancer chemotherapy. Nausea and vomiting are rated as two of the most 
distressing symptoms by chemotherapy patients and have been shown to  significantly and 
adversely affect quality of life and physical function during treatment.(Carelle et al., 2002; Sun 
et al., 2005) Ratings of quality of life can be reduced by as much as 20% in patients who 
experience CINV compared to symptom-free patients.(Lindley et al., 1992) Additionally, CINV 
is associated with malnutrition and further physical complications such as acid-base imbalance 
and electrolyte disturbances.(Davidson et al., 2012; Lindley and Hirsch, 1992; Osoba, 2005) All 
of these issues affect the patients’ ability to adhere to, or complete chemotherapy, resulting in a 
potential concomitant impact on survival outcomes.  
Despite significant improvement in the control of CINV through the use of modern anti-emetics 
such as 5-HT3 antagonists, corticosteroids and NK1 antagonists, nausea and vomiting still affects 
up to 60% and 37% of patients undergoing chemotherapy, respectively.(Bloechl-Daum et al., 
2006)   
Ginger has traditionally been used for centuries as a treatment for gastrointestinal complaints and 
more recently has been investigated for its use in treating motion sickness, post-operative nausea 
and vomiting, and morning sickness in clinical studies.(Ernst and Pittler, 2000) A recent 
systematic review of randomised-controlled trials that investigated the effect of ginger as an 
adjuvant treatment for CINV found that the literature was equivocal with significant 
limitations.(Marx et al., 2013)  
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An array of compounds are bioactive within the rhizome of ginger, such as shogaols, gingerols, 
zingerone, and paradols.(Baliga et al., 2011) These compounds are typically categorised into two 
classes: volatile oils and non-volatile pungent compounds. Both of these classes of compounds 
are contained within the oleoresin, the collective term for the oil and resin fraction of the 
rhizome. While the concentration of these compounds varies greatly depending on the country of 
origin, storage, and preparation of the ginger product, the gingerol and shogaol compounds are 
likely to be the primary components responsible for ginger’s pharmacological effects. These 
compounds are believed to interact with multiple areas implicated in the development of CINV. 
Specific properties of these compounds that may be relevant to CINV include 5-HT3, substance 
P and acetylcholine receptor antagonism; anti-inflammatory properties; and modulation of 
cellular redox signalling, vasopressin release, gastrointestinal motility, and gastric emptying 
rate.(Abdel-Aziz et al., 2006; Prakash and Srinivasan, 2010; Wu et al., 2008; Zick et al., 2011) 
Whereas recent reviews have focused upon the clinical efficacy of ginger, this paper will focus 
on the potential mechanisms by which ginger could exert anti-CINV effects.  
Physiology of CINV 
The physiology of CINV is a complex neural interaction involving central and peripheral stimuli 
and reactions. While multiple pathways are involved in CINV, this discussion will focus on the 
primary pathway of CINV (i.e 5-HT3 and NK1 antagonism) and pathways that could potentially 
be modulated by ginger (Figure 1). The site of the initial trigger of CINV is thought to be within 
the gastrointestinal tract. Chemotherapy agents interact with enterochromaffin cells, possibly via 
oxidative stress, resulting in a release of the neurotransmitters serotonin and substance P.(Torii et 
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al., 1994a) The released neurotransmitters then interact with receptors located upon the vagus 
nerve, which subsequently transmits afferent signals to the chemotherapy receptor zone within 
the brain via the nucleus tractus solitarius. It is thought that modern 5-HT3 antagonist 
medications (e.g. ondansetron) interact with the 5-HT3 receptors involved in this process, which 
then mitigates the degree of afferent signalling. Another neurotransmitter, substance P, has also 
been implicated in the generation of CINV by binding to NK1 receptors located centrally within 
the brain. Stimuli transmitted using these two neuropeptides, as well as stimuli from other 
regions of the brain, are processed by the chemoreceptor trigger zone and vomiting centre, which 
then coordinates the relevant musculature to induce a nausea and/or vomiting response.(Rudd, 
2005)  
While not directly involved in the generation of CINV, other secondary pathways could 
exacerbate the experience of nausea and vomiting in this setting. These include the modulation 
of gastric emptying, increased inflammation, and vestibular and vasopressin-related 
mechanisms.(Cawley and Benson, 2005; Rudd, 2005; Sharma and Gupta, 1998)  
Chemotherapy agents such as cisplatin and methotrexate are known to delay gastric emptying, 
potentially resulting in gastrointestinal distress due to antral distension.(Sharma and Gupta, 
1998) Research related to chemotherapy-induced mucositis has demonstrated that pro-
inflammatory signalling pathways, particularly nuclear factor kappa-B (NF-κB), are increased 
within the gastrointestinal mucosa as a result of chemotherapy-induced cell injury. It has been 
suggested that this increase in gut inflammation might contribute to the development of CINV, 
particularly during the delayed phase (≥24 hours after chemotherapy)(Rudd, 2005) which is 
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supported by the increase in inflammatory cytokines largely occurring between 2-10 days post-
chemotherapy.(Cawley and Benson, 2005)    
The vestibular system, which is located within the inner ear, is involved in providing a sense of 
balance. While the vestibular system might not be a primary pathway in the development of 
CINV, vestibular disturbances are implicated in the exacerbation of CINV. In support of this, the 
vestibular system is involved in the development of motion sickness, which is a known risk 
factor for CINV.(Leventhal et al., 1988) Furthermore, scopolamine, a pharmacological treatment 
for motion sickness, has demonstrated efficacy in reducing CINV when used in conjunction with 
other anti-emetic medications, but not when used as a stand-alone treatment.(Longo et al., 1982; 
Meyer et al., 1987) This suggests that the vestibular system plays a secondary role in the 
development of CINV.   
Lastly, it has been suggested that vasopressin (also known as antidiuretic hormone) contributes 
to the sensation of nausea in chemotherapy patients. Studies have demonstrated that vasopressin 
is significantly increased in patients experiencing CINV(Fisher et al., 1982; Rudd, 2005)  and 
that the  administration of supraphysiological doses of endogenous vasopressin is sufficient to 
induce nausea in healthy human participants.(Caras et al., 1997)  However, other studies do not 
support this hypothesis. For example, when vasopressin was administered at physiological doses, 
nausea was not experienced.(Kim et al., 1997) This has lead researchers to suggest that 
vasopressin may play a modulatory role in the generation of CINV instead.(Rudd, 2005)  
Proposed mechanisms of action 
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Interaction with neurotransmitters and vagal afferent signalling 
Results from in vitro and animal studies demonstrate that ginger is likely to exert 5-HT3 
antagonistic effects. Yamahara et al.(Yamahara et al., 1989) were the first to demonstrate that 
whole ginger, as well as 6-, 8- and 10-gingerols, could inhibit 5-HT3-induced contractions in an 
isolated guinea pig ileum. Huang et al.(Huang et al., 1991) demonstrated inhibition of 5-HT3-
induced contractions using the ginger compound, galanolactone. However, these two studies 
have significant limitations.(Abdel-Aziz et al., 2006) Both studies used serotonin to induce 
contractions, not an agonist that is selective for 5-HT3 receptors. This allows for the possibility 
that ginger inhibited the action of serotonin on another receptor, making the exact mechanism of 
action unclear.(Abdel-Aziz et al., 2006) 
 Additionally, Huang et al.(Huang et al., 1991) studied galanolactone, a compound only found in 
Japanese ginger and which therefore cannot be extrapolated to other types of ginger.(Abdel-Aziz 
et al., 2006; Ravindran and Babu, 2004)  
To address these limitations, Abdel-Aziz et al.(Abdel-Aziz et al., 2006) investigated the effect of 
four major compounds found in ginger, namely 6-, 8- and 10-gingerol and 6-shogaol, on 5-HT3-
mediated contractions in an isolated rat ileum using a selective 5-HT3 agonist. The results 
indicated that these compounds significantly inhibited contractions induced by this agonist; 
however, all four compounds failed to displace the 5-HT3 receptor antagonist, [3H]GR65630, 
from binding to the 5-HT3 receptor. It was therefore concluded that the mechanism of action of 
ginger, at least in relation to 5-HT3 pathways, is most likely due to indirect modulation of 5-HT3 
signalling through the binding of an alternative, unidentified site.(Abdel-Aziz et al., 2006) 
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Additionally, the authors reported that these compounds weakly inhibited acetyl-choline and 
substance P-induced contractions, suggesting additional mechanisms for the anti-CINV effects 
of ginger. 
Modulation of gastrointestinal motility and gastric emptying 
Metoclopramide has been used for decades as an anti-emetic in chemotherapy, partly due to its 
prokinetic effect on the gastrointestinal system.(Schapira et al., 1990) Research, particularly 
from in vitro studies, suggest that ginger is also likely to affect gastrointestinal motility and 
gastric emptying.(Hashimoto et al., 2002; Hu et al., 2011; Wu et al., 2008) While gastrointestinal 
dysmotility may not play a direct role in the generation of CINV, it may play a secondary role by 
contributing to other gastrointestinal symptoms such as bloating, early satiety, and abdominal 
pain.   
Multiple animal and in vitro studies indicate that whole ginger as well as specific compounds 
within ginger affect gastric emptying rates and gastrointestinal contractions. For example, 
Hashimoto et al.(Hashimoto et al., 2002) demonstrated that 6-shogaol improved muscle 
contractions and charcoal-induced transit time in porcine small intestines. Similarly, acetone 
ginger extract as well as the ginger components, 6-shogoal, 6-. 8-, and 10-gingerol, all enhanced 
the transport of a charcoal meal in mice.(Yamahara et al., 1990) Furthermore, both an ethanolic 
and acetone extract of ginger as well as ginger juice all reversed cisplatin-induced delayed 
gastric emptying in rats.(Sharma and Gupta, 1998)  In contrast, the ginger compounds zingerone 
and zingerol as well as whole ginger were reported to inhibit colonic motility in rats.(Iwami et 
al., 2011a; Iwami et al., 2011b) These diverse results indicate that ginger’s effects could be a 
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result of the particular concentration of different bioactive compounds, or the synergy between 
them.  
The effect of ginger on gastrointestinal motility in human participants has been investigated in 
multiple studies; however, the degree to which the results of these studies can be extrapolated to 
the CINV setting is limited as no study has been conducted with patients undergoing 
chemotherapy to date. This is likely due to CINV-related anti-emetic research focusing on other 
pathways (i.e 5-HT3-mediated CINV) and the burden that such a study may place on patients 
undergoing chemotherapy; however, relief from symptoms related to gastrointestinal dysmotility 
could prove to be effective as a secondary measure of CINV management and therefore, future 
research in the CINV setting is recommended.  
To date, six studies have examined the effect of ginger on gastrointestinal motility in varied 
patient populations, including healthy participants and participants with dyspepsia or admitted to 
an intensive care unit.(Hu et al., 2011; Micklefield et al., 1999; Phillips et al., 1993; 
Shariatpanahi et al., 2010; Stewart et al., 1991; Wu et al., 2008) However, the significant 
differences in methodology employed in these studies makes comparison difficult. Differences 
included the dosage of ginger, the composition of the test meal used, and the instrument used to 
measure gastric emptying and motility. Scintography is the recommended method to evaluate 
gastric empting.(Abell et al., 2008) However, due to the use of radioactive materials in this 
technique and the risk attendant on this, alternative methods are preferred.(Wu et al., 2008) 
While the use of alternative methods might reduce the equipment costs and expertise required, 
they are not as sensitive and could introduce confounders.  For example, in one study of 
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intensive care patients, when gastric emptying was measured by the amount of feeding tolerated 
over a 48 hour period by participants, ginger improved gastric motility.(Shariatpanahi et al., 
2010) However, in an another study that evaluated gastric emptying by a similarly indirect 
method (the measurement of paracetamol absorption), Phillips et al.(Phillips et al., 1993) found 
1g of ginger had no effect on gastric emptying. The indirect measures used in these two studies 
provided a lower level of precision. The results could also be influenced by other factors, such as 
the nutrient density of the test meal, its fluid and macronutrient content and its total volume. All 
of these factors can influence the rate of gastric emptying; hence, a nutrient-dense test meal is 
critical when measuring rates of gastric emptying.(Wu et al., 2008) Because no test meal was 
used in this study, significant delays in gastric emptying would not be expected.  A similarly 
non-nutrient-dense test meal was used in a study of the effect of 500mg of ginger on gastric 
emptying rates.(Stewart et al., 1991)  The failure of this study to demonstrate efficacy in relation 
to ginger could be a result of the 75kcal solution used as the test meal, which may have been 
insufficient to induce an effect.(Stewart et al., 1991) 
Wu et al.(Wu et al., 2008) and Hu et al.(Hu et al., 2011) addressed many of these limitations by 
using a dose of 1.2g of ginger and a test meal with a relatively high caloric content (118kcal in 
both studies). The two studies found that ginger was effective at reducing gastric emptying rates 
in both healthy and dyspeptic participants. A smaller dose of ginger (200mg) has also 
demonstrated effectiveness in increasing gastrointestinal motility in healthy 
volunteers.(Micklefield et al., 1999)  
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In summary, animal studies as well as most human studies conducted to date (66%) suggest 
ginger modulates the rate of gastric emptying and gastrointestinal motility. However, no studies 
so far have investigated the effect in participants undergoing chemotherapy and therefore, the 
applicability of these results to the chemotherapy setting is currently unclear.  
Anti-oxidant properties 
Oxidative stress, defined as an over production of reactive oxygen species, has been reported to 
be linked to the etiology of the emetic reflex. One of the initial steps in the generation of CINV is 
believed to be the generation of free radicals by chemotherapy agents within the gastrointestinal 
tract which in turn leads to the release of neurotransmitters from enterochromaffin cells.(Torii et 
al., 1994b)  This notion has led to investigations of the antioxidant activity of ginger. In vitro 
experiments have demonstrated the antioxidant kinetic behaviour of isolated compounds 
extracted from the dried rhizomes of ginger, subjected to a 1,1-diphenyl-2-picrylhydrazyl radical 
scavenging reaction.(Masuda et al., 2004) 
However, there are no clear human clinical trials or animal experiments that demonstrate that 
ginger extracts might modulate CINV via an antioxidant effect. Given that the oxidative 
stress/antioxidant theory of cellular metabolism has been challenged,(Linnane et al., 2007) an 
alternative plausible biochemical explanation for ginger’s effect on CINV is the rebalancing of 
the disrupted cellular oxido-reductase mechanism that often accompanies chemotherapy 
treatments.(Linnane et al., 2007) 
Anti-inflammatory properties 
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During chemotherapy, cell injury caused within the gastrointestinal tract (GIT) results in the 
release of multiple inflammatory factors including cyclooxygenase-2 (COX-2), interleukin-6 (IL-
6), and nuclear factor kappa-B (NF-kB). The end result of this pathway is continued tissue 
damage and potentially mucositis along the length of the GIT.(Sultani et al., 2012) It has been 
suggested that inflammation and cell injury may be particularly involved in the delayed phase of 
CINV.(Hesketh, 2005)  
In vitro research has found that multiple ginger compounds are able to elicit an anti-
inflammatory effect through a number of pathways including the inhibition of NF-kB, COX 
enzymes, and 5-lipoxogenase.(van Breemen et al., 2011) Ginger compounds have also 
demonstrated an anti-inflammatory effect in murine and rat models, with these effects replicated 
in human clinical trials.(Ojewole, 2006; Zick et al., 2011)  For example, 28 days of ginger 
supplementation (2g) in humans modulated eicosanoid synthesis in the colonic mucosa by 
lowering prostaglandin-2 levels in healthy participants(Zick et al., 2011) and COX-1 in 
participants who were at risk of colon cancer.(Jiang et al., 2012) Additionally, a review that 
included 8 clinical trials in this field concluded that while there is a paucity of well-designed 
trials, there is tentative evidence that ginger possesses anti-inflammatory properties in the 
treatment of pain related to osteoarthritis, dysmenorrhea, and exercise.(Terry et al., 2011)  
In summary, while these studies did not directly measure the effect of ginger on inflammation 
during chemotherapy, the current literature indicates that ginger is likely to modulate 
inflammation in the gut and this could contribute to ginger’s anti-CINV effects.   
Vestibular interactions 
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Acetylcholine and histamine are two neurotransmitters involved in the development of motion 
sickness. In vitro studies demonstrate that ginger compounds have antagonistic properties to both 
muscarinic and histaminergic receptors and therefore, represent a potential pathway by which 
ginger may interact with the vestibular system.(Abdel-Aziz et al., 2006) Clinical trials have 
largely confirmed this effect in clinical or experimentally-induced motion sickness. Eight trials 
were identified in our review, of which five reported ginger to be either superior to placebo or 
equal to standard anti-motion sickness medications. (Grontved et al., 1988; Grontved and 
Hentzer, 1986; Holtmann et al., 1989; Lien et al., 2003; Mowrey and Clayson, 1982; Schmid et 
al., 1994; Stewart et al., 1991; Wood et al., 1988) Therefore, it is likely that ginger is able to 
interact with signalling involved in the vestibular system and could potentially modulate CINV 
symptoms. 
Modulation of vasopressin 
Ginger is known to reduce plasma vasopressin in adults exposed to experimentally-induced 
motion sickness; however, when endogenous vasopressin was injected, ginger was ineffective in 
preventing nausea.(Lien et al., 2003) This suggests that ginger exerts an indirect action on 
vasopressin release. However, to date there is only one study measuring ginger’s effect on 
vasopressin. Future studies are required to confirm these effects in the chemotherapy setting. 
Furthermore, the exact role of vasopressin in CINV needs to be elucidated before this can be 
considered a clinically-relevant mechanism.  
Conclusion 
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CINV is a significant burden experienced by many oncology patients. While the control of overt 
vomiting has advanced, it is still prevalent and nausea remains stubbornly problematic for 
numerous chemotherapy patients. Ginger contains a wide array of bioactive compounds that can 
potentially act on multiple pathways involved in the physiology of CINV (Figure 1). These 
pathways include the modulation of relevant neuropeptides, vasopressin release and 
gastrointestinal motility as well as redox and anti-inflammatory signalling. The clinical evidence 
for its use in the treatment in CINV is currently equivocal;(Marx et al., 2013) however, the data 
presented in this paper demonstrate an array of viable mechanisms of action and provide a sound 
foundation for continued research in this area. Of primary importance is the need for future trials 
to investigate these beneficial properties in the chemotherapy setting.  
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Figure 1. Proposed anti-CINV mechanisms of action of ginger.  
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